GSA Capital Partners LLP Has $1.51 Million Position in Enzo Biochem, Inc. (ENZ)

GSA Capital Partners LLP cut its stake in Enzo Biochem, Inc. (NYSE:ENZ) by 16.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 144,091 shares of the medical research company’s stock after selling 27,600 shares during the period. GSA Capital Partners LLP owned 0.31% of Enzo Biochem worth $1,509,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in ENZ. Evermore Global Advisors LLC lifted its stake in Enzo Biochem by 3.7% in the third quarter. Evermore Global Advisors LLC now owns 3,685,520 shares of the medical research company’s stock valued at $38,587,000 after buying an additional 130,287 shares during the period. Dimensional Fund Advisors LP lifted its stake in Enzo Biochem by 6.0% in the third quarter. Dimensional Fund Advisors LP now owns 2,148,017 shares of the medical research company’s stock valued at $22,490,000 after buying an additional 121,370 shares during the period. Renaissance Technologies LLC lifted its stake in Enzo Biochem by 1.3% in the second quarter. Renaissance Technologies LLC now owns 2,069,600 shares of the medical research company’s stock valued at $22,848,000 after buying an additional 27,200 shares during the period. Vanguard Group Inc. lifted its stake in Enzo Biochem by 5.2% in the second quarter. Vanguard Group Inc. now owns 1,752,680 shares of the medical research company’s stock valued at $19,350,000 after buying an additional 86,922 shares during the period. Finally, State Street Corp lifted its stake in Enzo Biochem by 14.4% in the second quarter. State Street Corp now owns 667,535 shares of the medical research company’s stock valued at $7,373,000 after buying an additional 84,043 shares during the period. Institutional investors and hedge funds own 63.65% of the company’s stock.

Enzo Biochem, Inc. (NYSE:ENZ) opened at $8.77 on Wednesday. Enzo Biochem, Inc. has a 12 month low of $6.27 and a 12 month high of $12.04.

Enzo Biochem (NYSE:ENZ) last issued its quarterly earnings results on Thursday, December 7th. The medical research company reported ($0.01) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.01). Enzo Biochem had a negative return on equity of 1.89% and a negative net margin of 1.53%. The firm had revenue of $27.68 million for the quarter, compared to analyst estimates of $27.51 million. sell-side analysts forecast that Enzo Biochem, Inc. will post -0.02 EPS for the current fiscal year.

In other news, CEO Elazar Rabbani sold 72,401 shares of the company’s stock in a transaction that occurred on Wednesday, October 25th. The stock was sold at an average price of $10.09, for a total transaction of $730,526.09. Following the transaction, the chief executive officer now directly owns 2,038,474 shares of the company’s stock, valued at $20,568,202.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Barry W. Weiner sold 54,126 shares of the company’s stock in a transaction that occurred on Wednesday, October 25th. The stock was sold at an average price of $10.11, for a total value of $547,213.86. Following the transaction, the chief financial officer now directly owns 1,423,367 shares in the company, valued at $14,390,240.37. The disclosure for this sale can be found here. Over the last three months, insiders sold 191,398 shares of company stock worth $1,925,292. Insiders own 8.90% of the company’s stock.

Separately, TheStreet lowered Enzo Biochem from a “b” rating to a “c+” rating in a research note on Wednesday, September 27th.

TRADEMARK VIOLATION WARNING: “GSA Capital Partners LLP Has $1.51 Million Position in Enzo Biochem, Inc. (ENZ)” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.com-unik.info/2017/12/20/gsa-capital-partners-llp-has-1-51-million-position-in-enzo-biochem-inc-enz.html.

About Enzo Biochem

Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

Institutional Ownership by Quarter for Enzo Biochem (NYSE:ENZ)

What are top analysts saying about Enzo Biochem? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Enzo Biochem and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit